Stock Events

Stock Events

X.T.L. Biopharmaceuticals 

$2.35
9
-$0.18-7.29% 13:34 Today

Statistics

Day High
2.53
Day Low
2.53
52W High
10.28
52W Low
2.01
Volume
163
Avg. Volume
71,777
Mkt Cap
5.76M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

14MarExpected
Q2 2022
Q3 2022
Q4 2022
Q1 2023
Q2 2023
Q3 2023
Q4 2023
-0.15
-0.1
-0.05
0
Expected EPS
0
Actual EPS
0

Financials

-227.72%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
451,000Revenue
-1.03MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow XTLB. It's not an investment recommendation.
Plug Power
5
PLUG
Rocket Lab
4
RKLB
IonQ
4
IONQ
Quantum Computing
4
QUBT

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Gilead Sciences
GILD
Mkt Cap187.23B
Gilead Sciences is a biopharmaceutical company that develops and markets drugs in similar therapeutic areas as XTLB, including treatments for viral diseases.
AMGEN
AMGN
Mkt Cap236.38B
Amgen focuses on human therapeutics and has developed products in areas that overlap with XTLB's research interests, such as immunology and inflammation.
Biogen
BIIB
Mkt Cap32.63B
Biogen develops therapies for neurological and neurodegenerative diseases, competing directly with XTLB's focus on autoimmune diseases and immunotherapy.
Vertex Pharmaceuticals
VRTX
Mkt Cap138.42B
Vertex Pharmaceuticals concentrates on creating drugs for complex diseases, a similar approach to XTLB's focus on targeted therapeutic applications.
Regeneron Pharmaceuticals
REGN
Mkt Cap85.22B
Regeneron Pharmaceuticals is known for its innovation in biopharmaceuticals, directly competing with XTLB in the field of biologic therapies.
Incyte
INCY
Mkt Cap25.69B
Incyte specializes in oncology and inflammation, aligning closely with XTLB's research into immune response modulation.
Novartis
NVS
Mkt Cap304.1B
Novartis is a global healthcare company that develops treatments across a broad range of areas, including those targeted by XTLB.
Pfizer
PFE
Mkt Cap162.16B
Pfizer operates across various therapeutic areas, including immunology and oncology, overlapping with XTLB's therapeutic development strategies.

About

XTL Biopharmaceuticals Ltd is an intellectual property-based company focused on the development, management, and commercialization of intellectual property. The Company is engaged in biotechnology through its subsidiary Psyga Bio and in the biopharmaceutical industry with hCDR1, a novel compound working via a novel mechanism of action for the treatment of Systemic Lupus Erythematosus (SLE) and a potential treatment for Sjogren's syndrome (SS). It focuses on the acquisition and development of proprietary products and late-stage pharmaceutical product candidates for the treatment of unmet clinical needs.
Show more...
CEO
Noam Band
Employees
5
Country
Israel
ISIN
US98386D4060
WKN
000A41X7J

Listings

MU
DE
H2K2.MU
STU
DE
HHB0.STU
F
DE
HHB0.F
STU
DE
H2K2.STU

0 Comments

Share your thoughts

FAQ

What is X.T.L. Biopharmaceuticals stock price today?▼
The current price of XTLB is $2.35 USD — it has decreased by -7.29% in the past 24 hours. Watch X.T.L. Biopharmaceuticals stock price performance more closely on the chart.
What is X.T.L. Biopharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange X.T.L. Biopharmaceuticals stocks are traded under the ticker XTLB.
Is X.T.L. Biopharmaceuticals stock price growing?▼
XTLB stock has risen by +9.05% compared to the previous week, the month change is a -13.95% fall, over the last year X.T.L. Biopharmaceuticals has showed a -87.74% decrease.
What is X.T.L. Biopharmaceuticals market cap?▼
Today X.T.L. Biopharmaceuticals has the market capitalization of 5.76M
What were X.T.L. Biopharmaceuticals earnings last quarter?▼
XTLB earnings for the last quarter are 0 USD per share, whereas the estimation was 0 USD resulting in a +NaN% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is X.T.L. Biopharmaceuticals revenue for the last year?▼
X.T.L. Biopharmaceuticals revenue for the last year amounts to 451,000 USD.
What is X.T.L. Biopharmaceuticals net income for the last year?▼
XTLB net income for the last year is -1.03M USD.
How many employees does X.T.L. Biopharmaceuticals have?▼
As of September 08, 2026, the company has 5 employees.
In which sector is X.T.L. Biopharmaceuticals located?▼
X.T.L. Biopharmaceuticals operates in the Health & Wellness sector.
When did X.T.L. Biopharmaceuticals complete a stock split?▼
The last stock split for X.T.L. Biopharmaceuticals was on March 25, 2026 with a ratio of 1:4.
Where is X.T.L. Biopharmaceuticals headquartered?▼
X.T.L. Biopharmaceuticals is headquartered in Ramat Gan, Israel.